```html

Zollinger‑Ellison Syndrome (Gastrinoma‑Associated Hyperparathyroidism)

Overview

Zollinger‑Ellison syndrome (ZES) is a rare neuroendocrine disorder in which one or more gastrin‑producing tumors (gastrinomas) cause excessive gastric acid secretion. When these gastrinomas occur as part of the genetic condition multiple endocrine neoplasia type 1 (MEN 1), patients often develop hyperparathyroidism—the over‑production of parathyroid hormone (PTH) that raises calcium levels. This combined presentation is sometimes referred to as “gastrinoma‑associated hyperparathyroidism.”

• Incidence: Approximately 0.1–0.3 cases per 100,000 people per year worldwide.<sup>[1]</sup>
• Gender/Age: Slight male predominance (≈55 % male). Most sporadic cases are diagnosed between ages 30–60; MEN‑1‑associated cases often present in the 20s‑40s.<sup>[2]</sup>
• Geography: No strong ethnic or regional predilection; cases are reported globally.

Symptoms

Symptoms arise from two main physiologic disturbances: acid hypersecretion (caused by gastrinomas) and hypercalcemia (caused by hyperparathyroidism). The combination can make the clinical picture more severe.

Gastrinoma‑related symptoms

• Peptic ulcer disease (PUD): Multiple, recurrent, or treatment‑resistant ulcers in the duodenum, jejunum, or stomach.
• Abdominal pain: Cramping or gnawing pain that worsens 1–3 hours after meals.
• Diarrhea: Stools may be watery, fatty (steatorrhea), or cause “dumping” after meals because excess acid inactivates pancreatic enzymes.
• Nausea & vomiting: Often related to ulcer complications or gastric outlet obstruction.
• Gastro‑esophageal reflux disease (GERD): Burning chest pain, sour taste, or chronic cough.
• Weight loss: Due to malabsorption and reduced intake from pain.

Hyperparathyroidism‑related symptoms

• Hypercalcemia: Thirst, polyuria, constipation, fatigue, and mental clouding (“stones, bones, groans, and psychiatric overtones”).
• Kidney stones: Recurrent nephrolithiasis due to calcium precipitation.
• Bone pain & fractures: Osteopenia/osteoporosis from chronic bone resorption.
• Muscle weakness: Especially proximal muscle groups.

When both processes coexist

• Severe abdominal pain with concurrent polyuria.
• Recurrent ulcer perforation plus kidney stones.
• Worsening nutritional deficiencies (vitamin B12, iron) due to chronic diarrhea and malabsorption.

Causes and Risk Factors

ZES can be sporadic (≈70 % of cases) or occur as part of the hereditary syndrome MEN 1 (≈30 %).

Sporadic gastrinomas

• Arise from neuroendocrine cells in the duodenum (≈55 %) or pancreas (≈35 %).
• Exact molecular triggers are unclear, though mutations in the MEN1 gene (different from MEN 1 syndrome) have been described in a minority of tumors.

MEN 1‑associated gastrinomas

• MEN 1 (multiple endocrine neoplasia type 1) is an autosomal‑dominant disorder caused by germline mutations in the MEN1 tumor‑suppressor gene.
• Patients develop tumors in the parathyroid glands (≈90 %), pancreatic islet cells (including gastrinomas, ≈30‑40 %), and anterior pituitary (≈30 %).
• Family history, early‑onset hyperparathyroidism, or a known MEN1 mutation dramatically raise suspicion.

Risk factors

• Positive family history of MEN 1.
• Previous diagnosis of primary hyperparathyroidism.
• Chronic use of proton‑pump inhibitors (PPIs) does not cause ZES but may mask symptoms, delaying diagnosis.
• Smoking and heavy alcohol use can exacerbate ulcer disease but are not direct causes.

Diagnosis

Because ZES is rare and symptoms overlap with common GI disorders, a high index of suspicion is critical, especially in patients with refractory ulcers or concurrent hyperparathyroidism.

Initial laboratory evaluation

• Fasting serum gastrin: Levels > 1000 pg/mL (normal < 100 pg/mL) are highly suggestive, especially when gastric pH < 2.<sup>[3]</sup>
• Secretin stimulation test: An increase in gastrin > 120 pg/mL after IV secretin confirms gastrinoma in equivocal cases.
• Serum calcium & PTH: Elevated calcium (>10.2 mg/dL) with inappropriately high PTH indicates primary hyperparathyroidism.
• Basic metabolic panel, liver function tests, and CBC to assess overall health.

Imaging studies

• Endoscopic ultrasound (EUS): Highly sensitive for small pancreatic/duodenal lesions (< 1 cm).
• Multiphasic contrast‑enhanced CT or MRI: Provides anatomic detail and assesses metastatic spread.
• Somatostatin receptor scintigraphy (Octreoscan) or Gallium‑68 DOTATATE PET/CT: Detects neuroendocrine tumors that express somatostatin receptors; sensitivity > 90 % for gastrinomas.
• Bone scan or DEXA: Evaluate bone density when hyperparathyroidism is present.

Pathology

If surgical resection is performed, histologic examination confirms a neuroendocrine tumor (positive for chromogranin A, synaptophysin, and gastrin immunostaining). Ki‑67 proliferative index helps grade tumor aggressiveness.

Genetic testing

All patients with ZES and hyperparathyroidism—or a family history of MEN 1—should undergo germline MEN1 mutation analysis. Results guide screening of relatives and long‑term surveillance.

Treatment Options

Treatment aims to control acid hypersecretion, remove or control the tumor, and manage hyperparathyroidism.

Medical management of acid hypersecretion

• High‑dose proton‑pump inhibitors (PPIs): Omeprazole 60 mg bid, pantoprazole 80 mg bid, or equivalent. PPIs are the cornerstone; they heal ulcers and significantly improve quality of life.<sup>[4]</sup>
• Histamine‑2 receptor antagonists (H2RAs): May be added for breakthrough symptoms, but PPIs are preferred.
• Monitor magnesium, calcium, and vitamin B12 levels every 6–12 months, as chronic PPI use can cause deficiencies.

Surgical treatment of gastrinomas

• Localized disease: Enucleation or pancreaticoduodenectomy (Whipple) for pancreatic lesions; duodenal gastrinomas often require segmental duodenectomy.
• Metastatic disease: Liver‑directed therapies (resection, radiofrequency ablation, hepatic artery embolization) plus systemic options.
• Somatostatin analogs (SSA): Octreotide or lanreotide to inhibit gastrin release and control tumor growth; indicated when surgery isn’t feasible or to reduce recurrence.
• Targeted therapy: Everolimus or sunitinib for progressive metastatic neuroendocrine tumors (NETs) per NCCN guidelines.

Management of primary hyperparathyroidism

• Surgical parathyroidectomy: Preferred definitive treatment; minimally invasive focused parathyroidectomy is successful in > 95 % of sporadic cases.
• Medical control: When surgery is contraindicated, calcimimetics (cinacalcet) lower calcium levels; hydration and bisphosphonates help protect bone.

Lifestyle and supportive measures

• Small, frequent meals; avoid foods that trigger acid (spicy, caffeinated, alcohol).
• Stay well‑hydrated; limit calcium‑rich supplements if hypercalcemia is severe.
• Quit smoking; limit NSAID use which can exacerbate ulcer disease.
• Regular bone health monitoring (DEXA every 1–2 years).

Living with Zollinger‑Ellison Syndrome (gastrinoma‑associated hyperparathyroidism)

Long‑term management requires a multidisciplinary team—gastroenterology, endocrinology, surgery, nutrition, and genetics.

Daily management tips

• Medication adherence: Take PPIs exactly as prescribed; don’t skip doses.
• Symptom diary: Record pain, stool pattern, and any signs of hypercalcemia (e.g., excessive thirst, confusion).
• Nutrition:
  • Consume a balanced diet with adequate protein, low‑fat, and complex carbohydrates.
  • Consider a dietitian’s guidance for fat‑soluble vitamin supplementation (A, D, E, K).
• Hydration: Aim for ≥ 2 L of water daily unless fluid restriction is mandated for cardiac/renal disease.
• Bone health: Ensure daily calcium (800–1000 mg) and vitamin D (800–1000 IU) unless hypercalcemia is uncontrolled; discuss dosing with your endocrinologist.
• Regular follow‑up:
  • Endoscopy every 1–3 years to monitor ulcer healing.
  • Serum gastrin and calcium/PTH every 6‑12 months.
  • Imaging (CT/MRI or DOTATATE PET) annually if disease is metastatic.

Psychosocial coping

Living with a chronic rare disease can be stressful. Connecting with patient support groups (e.g., Zollinger‑Ellison Support Network) and mental‑health professionals can improve quality of life.

Prevention

Because most cases are sporadic, primary prevention is limited. However, risk reduction strategies include:

• Early screening of first‑degree relatives when a MEN1 mutation is identified.
• Prompt evaluation of persistent/recurrent ulcers, especially in patients under 40 or those not responding to standard therapy.
• Avoiding excessive NSAID or aspirin use without gastro‑protection.

Complications

If untreated or inadequately controlled, ZES with hyperparathyroidism can lead to serious health problems:

• Refractory or perforated peptic ulcers: May cause intra‑abdominal infection, peritonitis, or bleeding.
• Gastrointestinal bleeding: From ulcer erosion into vessels.
• Malabsorption & nutritional deficiencies: Iron, folate, B12, and fat‑soluble vitamins.
• Kidney stones & renal failure: Chronic hypercalcemia precipitates calculi and nephrocalcinosis.
• Osteoporosis & fractures: Long‑standing bone resorption.
• Neuroendocrine tumor metastasis: Liver involvement is the most common; can cause hepatic insufficiency.
• Neuropsychiatric effects: Hypercalcemia can cause confusion, depression, or psychosis.

When to Seek Emergency Care

References

1. Ramirez R, et al. Clinical presentation and management of Zollinger‑Ellison syndrome. PMC5606853. 2017.
2. Mayo Clinic. Zollinger‑Ellison Syndrome. Updated 2023.
3. Cleveland Clinic. Zollinger‑Ellison Syndrome. 2022.
4. Shin J, et al. High‑dose PPIs in the treatment of gastrinoma‑induced acid hypersecretion. PMC6929609. 2020.
5. National Comprehensive Cancer Network (NCCN). Neuroendocrine and Pancreatic Tumors Guidelines. Version 2.2024.
6. World Health Organization. Calcium and Vitamin D fact sheet. 2022.

```